LT3021873T - Kompozicija, skirta uždegiminių sąnarių ligų gydymui - Google Patents

Kompozicija, skirta uždegiminių sąnarių ligų gydymui

Info

Publication number
LT3021873T
LT3021873T LTEP14826787.5T LT14826787T LT3021873T LT 3021873 T LT3021873 T LT 3021873T LT 14826787 T LT14826787 T LT 14826787T LT 3021873 T LT3021873 T LT 3021873T
Authority
LT
Lithuania
Prior art keywords
treatment
composition
joint disease
inflammatory joint
inflammatory
Prior art date
Application number
LTEP14826787.5T
Other languages
English (en)
Inventor
Raymond Chavez
Linda Watkins
Robert Landry
Original Assignee
Xalud Therapeutics, Inc.
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xalud Therapeutics, Inc., The Regents Of The University Of Colorado, A Body Corporate filed Critical Xalud Therapeutics, Inc.
Publication of LT3021873T publication Critical patent/LT3021873T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP14826787.5T 2013-07-18 2014-07-17 Kompozicija, skirta uždegiminių sąnarių ligų gydymui LT3021873T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361847851P 2013-07-18 2013-07-18
PCT/US2014/047071 WO2015009955A1 (en) 2013-07-18 2014-07-17 Methods for the treatment of inflammatory joint disease

Publications (1)

Publication Number Publication Date
LT3021873T true LT3021873T (lt) 2018-11-26

Family

ID=52346725

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14826787.5T LT3021873T (lt) 2013-07-18 2014-07-17 Kompozicija, skirta uždegiminių sąnarių ligų gydymui
LTEP18167083.7T LT3369435T (lt) 2013-07-18 2014-07-17 Kompozicija uždegiminės sąnarių ligos gydymui

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP18167083.7T LT3369435T (lt) 2013-07-18 2014-07-17 Kompozicija uždegiminės sąnarių ligos gydymui

Country Status (15)

Country Link
US (4) US10512672B2 (lt)
EP (2) EP3021873B8 (lt)
JP (4) JP2016525522A (lt)
CY (2) CY1120946T1 (lt)
DK (2) DK3021873T3 (lt)
ES (2) ES2700826T3 (lt)
HR (2) HRP20181913T1 (lt)
HU (2) HUE042463T2 (lt)
LT (2) LT3021873T (lt)
PL (2) PL3021873T3 (lt)
PT (2) PT3369435T (lt)
RS (2) RS57974B1 (lt)
SI (2) SI3021873T1 (lt)
SM (2) SMT201900657T1 (lt)
WO (1) WO2015009955A1 (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3021873T (lt) 2013-07-18 2018-11-26 Xalud Therapeutics, Inc. Kompozicija, skirta uždegiminių sąnarių ligų gydymui
DK3445849T3 (da) * 2016-04-22 2024-08-05 Xalud Therapeutics Inc Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10
MX2022016548A (es) * 2020-06-26 2023-03-14 Amgen Inc Muteínas de il-10 y proteínas de fusión de las mismas.
WO2023114958A1 (en) * 2021-12-16 2023-06-22 Xalud Therapeutics, Inc. Dosing regimen for il-10 encoding expression construct

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
MY111402A (en) 1992-08-20 2000-04-29 Schering Corp Novel uses of il-4 and/or il-10, and antibodies against the same
US5922018A (en) 1992-12-21 1999-07-13 Artann Corporation Method for using a transrectal probe to mechanically image the prostate gland
US5373317B1 (en) 1993-05-28 2000-11-21 Welch Allyn Inc Control and display section for borescope or endoscope
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6159937A (en) 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US5716804A (en) 1995-04-19 1998-02-10 Schering Corporation Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
WO1998024469A1 (en) 1996-12-05 1998-06-11 University Of Florida Il-10 and tgf-beta for treating autoimmune disease
US6201880B1 (en) 1996-12-31 2001-03-13 Electro-Optical Sciences Method and apparatus for electronically imaging a tooth through transillumination by light
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999047157A1 (en) 1998-03-17 1999-09-23 Schering Corporation Use of il-10 to treat major depressive disorder
JP2002513775A (ja) 1998-05-06 2002-05-14 トランジェーヌ、ソシエテ、アノニム 細胞の中へのポリヌクレオチドのトランスフェクションを改良する治療組成物を調製するためのヌクレアーゼインヒビターまたはインターロイキン−１０（ｉｌ−１０）の使用、および遺伝子治療に有用な組成物
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6165754A (en) 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
US20050129669A1 (en) 1999-06-21 2005-06-16 Transkaryotic Therapies, Inc., A Massachusetts Corporation DNA construct for effecting homologous recombination and uses thereof
WO2001080897A2 (en) 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
AU2002217929A1 (en) 2000-11-28 2002-06-11 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
ATE309788T1 (de) 2000-12-13 2005-12-15 Merckle Gmbh Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002087594A1 (en) 2001-04-30 2002-11-07 The Regents Of The University Of California Non-viral vesicle vector for cardiac specific gene delivery
JP4578735B2 (ja) 2001-08-28 2010-11-10 オリンパス株式会社 内視鏡画像ファイリングシステム
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
JP2003146909A (ja) 2001-11-07 2003-05-21 Children's Hospital Of Philadelphia 治療用ポリペプチドに対する免疫寛容の誘導
WO2003059396A1 (en) 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
US20040186357A1 (en) 2002-08-20 2004-09-23 Welch Allyn, Inc. Diagnostic instrument workstation
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
US20040142893A1 (en) 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7530946B2 (en) 2003-08-15 2009-05-12 Scimed Life Systems, Inc. Compact endoscope
US7276486B2 (en) 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
KR20070058441A (ko) * 2004-07-01 2007-06-08 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 면역억제성 엑소솜
US20060073119A1 (en) 2004-09-01 2006-04-06 Avigen, Inc. Methods for treating neurodegenerative disorders
WO2006119170A2 (en) 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
JP4992025B2 (ja) 2005-05-31 2012-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 変異体ｉｌ−１０
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
WO2007016501A2 (en) 2005-08-01 2007-02-08 The University Of Chicago Compositions and method for brain specific targeted delivery of therapeutic agents
WO2008109806A2 (en) 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
US7846428B2 (en) 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
MX2013006708A (es) 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
WO2013103966A1 (en) 2012-01-06 2013-07-11 The Regents Of The University Of Colorado, A Body Corporate Methods for the treatment of multiple sclerosis and other demyelinating disorders
LT3021873T (lt) 2013-07-18 2018-11-26 Xalud Therapeutics, Inc. Kompozicija, skirta uždegiminių sąnarių ligų gydymui
DK3445849T3 (da) 2016-04-22 2024-08-05 Xalud Therapeutics Inc Fremgangsmåder og sammensætninger til at forbedre de anti-inflammatoriske virkninger af Interleukin-10

Also Published As

Publication number Publication date
JP2022031682A (ja) 2022-02-22
JP7066669B2 (ja) 2022-05-13
HUE046944T2 (hu) 2020-03-30
JP2020037562A (ja) 2020-03-12
ES2760902T3 (es) 2020-05-18
HRP20192043T1 (hr) 2020-02-07
EP3021873B8 (en) 2018-10-24
CY1122673T1 (el) 2021-03-12
JP2025023096A (ja) 2025-02-14
US20220313785A1 (en) 2022-10-06
PL3369435T3 (pl) 2020-04-30
CY1120946T1 (el) 2019-12-11
US20230158114A1 (en) 2023-05-25
EP3021873A4 (en) 2016-11-30
LT3369435T (lt) 2020-01-10
HUE042463T2 (hu) 2019-07-29
EP3369435A1 (en) 2018-09-05
EP3369435B1 (en) 2019-09-04
DK3369435T3 (da) 2019-11-25
RS59735B1 (sr) 2020-02-28
JP2016525522A (ja) 2016-08-25
US20160235816A1 (en) 2016-08-18
PT3021873T (pt) 2018-12-10
US10512672B2 (en) 2019-12-24
SI3369435T1 (sl) 2020-03-31
EP3021873B1 (en) 2018-09-05
EP3021873A1 (en) 2016-05-25
PT3369435T (pt) 2019-12-05
WO2015009955A1 (en) 2015-01-22
DK3021873T3 (en) 2018-12-17
HRP20181913T1 (hr) 2019-01-11
SMT201900657T1 (it) 2020-01-14
SI3021873T1 (sl) 2018-12-31
US20200093892A1 (en) 2020-03-26
SMT201800655T1 (it) 2019-01-11
ES2700826T3 (es) 2019-02-19
PL3021873T3 (pl) 2019-01-31
RS57974B1 (sr) 2019-01-31

Similar Documents

Publication Publication Date Title
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL243976B (en) kdm1a inhibitors for disease treatment
SG11201507459YA (en) Heterocyclic compounds useful in the treatment of disease
EP2990419A4 (en) Preventive or therapeutic agent for inflammatory disease
PL2996704T3 (pl) Kompozycja do ochrony stawów
ZA201604225B (en) Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus
ZA201507724B (en) The treatment of inflammatory disorders
PL3021873T3 (pl) Kompozycja do leczenia choroby zapalnej stawów
HUE042691T2 (hu) Tiazolo-pirimidinon felhasználása gyulladásos bélbetegségek kezeléséhez
GB201315079D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314016D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases